AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 241 min read$MAIA

Guerrero Ramiro purchased $16K of MAIA

Guerrero Ramiro purchased 11,899 shares of MAIA Biotechnology, Inc. (MAIA) at $1.37 on 2026-08-20.

Original reporting
SEC EDGAR · Guerrero Ramiro
Published Aug 24, 2026, 8:09 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 24, 2026, 8:26 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$MAIA
Neutral
high confidence
Mentioned
$MAIA
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MAIANeutralLow
01

Why it matters

The director's purchase modestly raises his ownership, offering limited insight into company prospects.

02

Market read

Minor insider purchase with negligible effect on MAIA's stock price.

03

What to watch

Potential upcoming clinical trial data may be the real driver, not the purchase itself.

Relevance 4/10Novelty 4/10Timing: filed 2026-08-24

Background

Form 4 filing discloses insider transactions; used by traders to gauge insider sentiment.

Company-level read

Ticker impact

$MAIANeutralHigh confidence
Context

Director Guerrero Ramiro bought 11,899 shares at $1.37, increasing his stake to 600,117 shares.

Expected impact

Minimal short-term price movement expected.

Evidence & confidence

Purchase amount (~$16k) is trivial for a listed biotech; unlikely to move price materially.

Market effects

Sector

No immediate sector impact; insider activity typical for biotech.

Regional

None

Global

None

Counterpoint

What could challenge this read

Insider buying could hint at upcoming positive news, but size is too small to be meaningful.

Key entities

  • Company
    MAIA Biotechnology, Inc.

    US-listed biotech company.

  • Insider
    Guerrero Ramiro

    Director of MAIA.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

MAIA insider trading history →

Related articles

SEP 2
$UPCMed

6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More

Universe Pharmaceuticals (UPC) rose 34.89% after-hours due to multiple Schedule 13G filings. BioAffinity (BIAF) explores new uses for its CyPath Lung test, up 3%. Modular Medical (MODD) gained 7% after announcing a product launch. MAIA (MAIA) rose 6% following an insider purchase. Telix (TLX) completed a Phase 3 study, up 2.21%. aTyr Pharma (ATYR) awaits FDA response, up 4%.

rttnews.com2 min
JUL 8
$MAIAMedAI 8/10

MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial

MAIA Biotechnology (NYSE American: MAIA) reported initial Phase 2 THIO-101 Part C data in third-line advanced NSCLC. Ateganosine followed by cemiplimab (Libtayo) produced a 90.5% disease control rate (19/21) in 3L patients, compared with 25-35% for standard chemotherapy. MAIA said safety is acceptable and enrollment is completed internationally.

manilatimes.net2 min